Cushing’s Syndrome in a Child with Pancreatic Acinar Cell Carcinoma

2007 ◽  
Vol 18 (2) ◽  
pp. 95-102 ◽  
Author(s):  
György Illyés ◽  
Andrea Luczay ◽  
Gábor Benyó ◽  
Attila Kálmán ◽  
Katalin Borka ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Cushing’S Syndrome ◽  
Acinar Cell Carcinoma ◽  
Cushing's Syndrome ◽  
Pancreatic Acinar Cell ◽  
Pancreatic Acinar Cell Carcinoma

The CT findings of pancreatic acinar cell carcinoma in five cases

2013 ◽  
Vol 37 (2) ◽  
pp. 302-307 ◽  
Author(s):  
Kefu Liu ◽  
Weijun Peng ◽  
Zhengrong Zhou
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Ct Findings ◽  
Pancreatic Acinar Cell Carcinoma

scholarly journals Alpha-fetoprotein-producing Pancreatic Acinar Cell Carcinoma

2007 ◽  
Vol 106 (8) ◽  
pp. 669-672 ◽  
Author(s):  
Yang-Chao Lin ◽  
Po-Huang Lee ◽  
Yu-Tung Yao ◽  
Jong-Kai Hsiao ◽  
Jin-Chuan Sheu ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Alpha Fetoprotein ◽  
Pancreatic Acinar Cell Carcinoma

Pancreatic acinar cell carcinoma in familial adenomatous polyposis

1996 ◽  
Vol 3 (1) ◽  
pp. 71-73 ◽  
Author(s):  
Takashi Ohsato ◽  
Ryuichi Mibu ◽  
Eishi Nagai ◽  
Hiroshi Satoh ◽  
Mitsuo Iida ◽  
...  
Keyword(s):  
Familial Adenomatous Polyposis ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Adenomatous Polyposis ◽  
Pancreatic Acinar Cell Carcinoma

scholarly journals Primary unresectable pancreatic acinar cell carcinoma which became resectable after S-1 and Oxaliplatin treatment

Suizo ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 270-278
Author(s):  
Taro MASHIKO ◽  
Kohei TAJIMA ◽  
Naoki YAZAWA ◽  
Yoshihito MASUOKA ◽  
Toshio NAKAGOHRI
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Oxaliplatin Treatment ◽  
Pancreatic Acinar Cell Carcinoma

scholarly journals Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literatures

2021 ◽  
Author(s):  
Jianying Xu ◽  
Wenlong Guan ◽  
Shixun Lu ◽  
Xiaoli Wei ◽  
Wenjie Shi ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Maintenance Treatment ◽  
Objective Response ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Cancer Center ◽  
Pancreatic Acinar Cell Carcinoma ◽  
Line Chemotherapy

Abstract Background: Pancreatic acinar cell carcinoma (PACC) is rare and its appropriate treatment remains unknown dued to limited and selection-biased dataMethods: The data on clinicopathologic characteristics, molecular alteration, treatment and survival of patients diagnosed as PACC in Sun Yat-sen university cancer center from 2005 to 2020 were collected. We explored the optimal treatment by co-analyzing our results and published literatures.Results: 22 PACC patients were enrolled. 8/17 non-metastatic patients received adjuvant chemotherapy. The patients receiving fluoropyrimidine-based regimen (n=3) had better mDFS than those with gemcitabine-based regimen (n=5) (unreached vs. 27 months). 8 metastatic patients received 1st-line chemotherapy. 4/5 patients with FOLFIRINOX regimen achieved partial response (PR) and 3 patients with AG (albumin paclitaxel+gemcitabine) regimen got progressive disease (PD). 4 patients received 2nd-line chemotherapy. 2 patients with FOLFIRINOX regimen achieved PR while 2 patients with AG regimen got PD. One patient who had responded to 1st-line FOLFIRINOX regimen received Olaparib as maintenance treatment for 5 months with good tolerance. 31 published literatures and a total of 86 cases were included in the co-analysis. Objective response rate of 1st-line fluoropyrimidine-based regimen (n=47) was higher than that of gemcitabine-based regimen (n=39) (59.6% vs.15.3%, P<0.001). 8/11 patients treated with FOLFIRINOX regimen achieved PR. Conclusions: The benefit of adjuvant chemotherapy remained unclear; however, fluoropyrimidine-based chemotherapy deserves attention. For metastatic patients, fluorouracil-based regimen such as FOLFIRINOX is preferred, and maintenance treatment of PARP inhibitors after effective platinum-containing treatment for BRAC mutation patients is worthy of exploration.

scholarly journals Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy

2018 ◽  
Vol 57 (24) ◽  
pp. 3529-3535 ◽  
Author(s):  
Naoki Yoshida ◽  
Atsushi Kanno ◽  
Atsushi Masamune ◽  
Tatsuhide Nabeshima ◽  
Seiji Hongo ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Pancreatic Acinar Cell Carcinoma ◽  
Multiple Liver Metastases

BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma

Pathology ◽  
2018 ◽  
Vol 50 (3) ◽  
pp. 345-348 ◽  
Author(s):  
Angela Chou ◽  
Yoomee Kim ◽  
Jaswinder S. Samra ◽  
Marina Pajic ◽  
Anthony J. Gill
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Gene Rearrangements ◽  
Braf Gene ◽  
Pancreatic Acinar Cell Carcinoma

Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma

2022 ◽  
Author(s):  
Paul R. Burchard ◽  
Alexander C. Chacon ◽  
Alexa Melucci ◽  
Anthony S. Casabianca ◽  
Subir Goyal ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Acinar Cell ◽  
Systemic Therapy ◽  
Acinar Cell Carcinoma ◽  
Pancreatic Acinar Cell ◽  
Pancreatic Acinar Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document